Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3368]

$European Commission approves tafasitamab for the treatment of relapsed or refractory follicular lymphoma$

European Commission approves tafasitamab for the treatment of relapsed or refractory follicular lymphoma

mRNA revitalises aging immune systems: The liver as a fountain of youth

mRNA revitalises aging immune systems: The liver as a fountain of youth

New understanding of T cell receptors may improve cancer immunotherapies

New understanding of T cell receptors may improve cancer immunotherapies

Keeping the heart healthy increases longevity even after cancer

Keeping the heart healthy increases longevity even after cancer

Study finds childhood leukaemia aggressiveness depends on timing of genetic mutation

Study finds childhood leukaemia aggressiveness depends on timing of genetic mutation

Researchers identify strategy for reducing risk of acute graft-versus-host disease for many with blood cancers

Researchers identify strategy for reducing risk of acute graft-versus-host disease for many with blood cancers

$FDA approves lisocabtagene maraleucel for relapsed or refractory marginal zone lymphoma$

FDA approves lisocabtagene maraleucel for relapsed or refractory marginal zone lymphoma

Researchers develop next-generation CAR T cells that show stronger, safer response in animal models

Researchers develop next-generation CAR T cells that show stronger, safer response in animal models

ASH 2025: Milder chemo works for rare, aggressive lymphoma

ASH 2025: Milder chemo works for rare, aggressive lymphoma

ASH 2025: New combination approach aims to make CAR T more durable in lymphoma

ASH 2025: New combination approach aims to make CAR T more durable in lymphoma

More from ecancer